Equities

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB

Actions
  • Price (SEK)1.67
  • Today's Change-0.06 / -3.48%
  • Shares traded1.80k
  • 1 Year change-16.54%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments191021
Total Receivables, Net0.670.230.25
Total Inventory------
Prepaid expenses0.260.570.24
Other current assets, total------
Total current assets201121
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term0.050.050.05
Other long term assets------
Total assets201121
LIABILITIES
Accounts payable1.311.364.49
Accrued expenses0.530.860.83
Notes payable/short-term debt000
Current portion long-term debt/capital leases012--
Other current liabilities, total0.520.140.14
Total current liabilities2.36145.46
Total long term debt000
Total debt0120
Deferred income tax------
Minority interest------
Other liabilities, total----0.00
Total liabilities2.36145.46
SHAREHOLDERS EQUITY
Common stock2.160.970.97
Additional paid-in capital333296296
Retained earnings (accumulated deficit)(317)(299)(281)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total----0.00
Total equity18(2.59)16
Total liabilities & shareholders' equity201121
Total common shares outstanding361616
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.